glp-1 by ro launches the Supply Tracker Interested in GLP-1s for weight

It is distinct from Rybelsus (lower-dose oral semaglutide for type 2 diabetes) and, following MHRA approval in June 2026, is rolling out on private prescription during the second half of 2026 rather than on the NHS

May your thyroid levels stay stable, your inflammation stay low, and your protocols stay informed.

GLP-1 agonists and GIP antagonists GIP antagonism is also a potential obesity treatment as in preclinical studies improved the metabolic profile and reduced food intake [54,55,56]

Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ et al (2021) Obesity and cardiovascular disease: a scientific statement from the american heart association